Article
Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017.
Cancer letters - 28 Jan 2021
Ding Ding, Javed Ammar A, Cunningham Dea, Teinor Jonathan, Wright Michael, Javed Zunaira N, Wilt Cara, Parish Lindsay, Hodgin Mary, Ryan Amy, Judkins Carol, McIntyre Keith, Klein Rachel, Azad Nilo, Lee Valerie, Donehower Ross, De Jesus-Acosta Ana, Murphy Adrian, Le Dung T, Shin Eun Ji, Lennon Anne Marie, Khashab Mouen, Singh Vikesh, Klein Alison P, Roberts Nicholas J, Hacker-Prietz Amy, Manos Lindsey, Walsh Christi, Groshek Lara, Brown Caitlin, Yuan Chunhui, Blair Alex B, Groot Vincent, Gemenetzis Georgios, Yu Jun, Weiss Matthew J, Burkhart Richard A, Burns William R, He Jin, Cameron John L, Narang Amol, Zaheer Atif, Fishman Elliot K, Thompson Elizabeth D, Anders Robert, Hruban Ralph H, Jaffee Elizabeth, Wolfgang Christopher L, Zheng Lei, Laheru Daniel A
Abstract excerpt
Recent research on genomic profiling of pancreatic ductal adenocarcinoma (PDAC) has identified many potentially actionable alterations. However, the feasibility of using genomic profiling to guide routine clinical decision making for PDAC patients remains unclear. We retrospectively reviewed PDAC patients between October 2013 and December 2017, who underwent treatment at the Johns Hopkins Hospital and had...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.